Art. -Nr.: HY-190489

MV14

MV14 is a small-molecule NO donor that exhibits selective antiproliferative activity against bladder cancer cells. MV14 releases NO, causing DNA double-strand damage, inhibiting the NF‑κB pathway, and downregulating the apoptosis-inhibitory protein Survivin. MV14 interferes with the cell cycle and promotes tumor cell apoptosis. MV14 attenuates tumor-associated histopathological changes, urothelial destruction, and stromal invasion in the BBN (HY-W755252)-induced mouse bladder cancer model, and reduces PCNA levels in bladder tumor tissue while increasing active caspase-3. MV14 can be used for research on bladder cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2377778-85-1
Formel: C₁₅H₁₉N₃O₇S
Molecular Weight:385.39

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

MV14 Chemical Structure

CAS. Nr.: 2377778-85-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
RT-4	IC50	0.20 μM	Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 24 hrs by MTT assay. Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 24 hrs by MTT assay.	42790168
RT-4	IC50	0.32 μM	Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 48 hrs by MTT assay. Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 48 hrs by MTT assay.	42790168
RT-4	IC50	0.34 μM	Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 72 hrs by MTT assay. Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 72 hrs by MTT assay.	42790168
T-24	IC50	0.89 μM	Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 24 hrs by MTT assay. Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 24 hrs by MTT assay.	42790168
T-24	IC50	0.73 μM	Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 48 hrs by MTT assay. Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 48 hrs by MTT assay.	42790168
T-24	IC50	0.69 μM	Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 72 hrs by MTT assay. Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 72 hrs by MTT assay.	42790168

In Vitro

Anti-cancerCell Cycle RegulationInnate ImmunityCytokines & ChemokinesOxidative StressOthers

Anti-cancer

MV14 (0.09-12.5 μM; 24-72 h) reduces the viability of RT4, T24, and 253J bladder cancer cells, with IC₅₀ values in the submicromolar range over 24-72 h, whereas the IC₅₀ value in SV-HUC-1 non-malignant urothelial cells is approximately 1.06-1.08 μM^[1].
MV14 (0.19-6.25 μM; 24 h) exerts antiproliferative activity against T24 and 253J bladder cancer cells that is partly contributed by NO release, with T24 cells showing higher sensitivity to NO scavenging^[1].
MV14 (0.39-3.13 μM; 24 h) inhibits the migration of T24 bladder cancer cells^[1].
MV14 (5-10 μM; 3 h) induces concentration-dependent γ-H2AX DNA damage in T24 and 253J bladder cancer cells, and NO release is involved in this effect^[1].
MV14 (0.39-1.56 μM (T24); 0.09-0.39 μM (253J); 24 h) reduces nuclear survivin in T24 and 253J bladder cancer cells^[1].
MV14 (1.56-3.13 μM; 24 h) reduces total survivin protein in T24 bladder cancer cells^[1].

Anti-cancer

Cell Cycle Regulation

MV14 (0.78-3.13 μM (T24); 0.19-0.78 μM (253J); 24 h) induces G2/M phase accumulation in T24 cells and S phase arrest in 253J bladder cancer cells^[1].

Innate Immunity

Cytokines & Chemokines

MV14 (5-10 μM; 1 h) inhibits TNF-α-induced NF-κB activation in HT-29-NF-κB-hrGFP reporter cells without intrinsic pro-inflammatory activity^[1].

Oxidative Stress

MV14 (100 μM), as an NO donor, exhibits sustained release kinetics, being detectable from 15 min and persisting until 24 h^[1].

Others

MV14 shows no mutagenicity against Salmonella typhimurium TA97a, TA98, TA100, TA1535, and Escherichia coli WP2 uvrA at concentrations of 1-100 μg/plate^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

RT4, T24, and 253J human bladder cancer cell lines and SV-HUC-1 non-malignant urothelial cells
Concentration:

RT4: 0.39, 0.78, 1.56, 3.13, 6.25, 12.50 μM
T24: 0.09, 0.19, 0.39, 0.78, 1.56, 3.13, 6.25, 12.50 μM
253J: 0.09, 0.19, 0.39, 0.78, 1.56, 3.13, 6.25, 12.50 μM
SV-HUC-1: 0.39, 0.78, 1.56, 3.13, 6.25, 12.50 μM
Incubation Time:

24, 48, and 72 h
Result:

Reduced viability of RT4, T24, and 253J bladder cancer cells with submicromolar IC₅₀ values across 24-72 h, including 0.25 μM in 253J at 72 h, while SV-HUC-1 non-malignant urothelial cells show IC₅₀ values of approximately 1.06-1.08 μM.

Cell Proliferation Assay^[1]

Cell Line:

T24 and 253J bladder cancer cells
Concentration:

0.19, 0.39, 0.78, 1.56, 3.13, 6.25 μM
50 μM (Hb (HY-P2995))
Incubation Time:

1 h (Hb pre-exposure); 24 h (MV14 exposure)
Result:

Reduced cell proliferation in a concentration‑dependent fashion. Diminished antiproliferative potency in both T24 and 253J cells upon 50 μM Hb treatment, with a more pronounced effect observed in T24 cells. Partially recovered inhibitory activity at the highest tested concentrations in 253J cells.

Cell Migration Assay ^[1]

Cell Line:

T24 bladder cancer cells
Concentration:

0.39, 0.78, 1.56, 3.13 μM
Incubation Time:

24 h
Result:

Reduced wound‑closure efficiency in a concentration‑dependent manner, lowering wound‑closure rates to 67 % at 0.39 μM and 21 % at 3.13 μM.
Suppressed T24 cell migration, producing stronger inhibitory effects at 0.78 μM, 1.56 μM and 3.13 μM.

Cell Cycle Analysis^[1]

Cell Line:

T24 and 253J bladder cancer cells
Concentration:

0.78, 1.56, 3.13 μM (T24)
0.19, 0.39, 0.78 μM (253J)
Incubation Time:

24 h
Result:

Exhibited dose‑dependent G0/G1‑phase reduction and G2/M‑phase elevation in T24 cells, indicating DNA‑damage‑related checkpoint activation and potential premitotic arrest.
Produced dose‑dependent G0/G1‑phase decline and marked S‑phase accumulation with unaltered G2/M fraction in 253J cells, pointing to replicative stress and S‑phase cell retention.

Immunofluorescence^[1]

Cell Line:

T24 and 253J bladder cancer cells
Concentration:

5, 10 μM
100 μM (Hb pretreatment)
Incubation Time:

3 h
Result:

Induced concentration-dependent γ-H2AX DNA damage in T24 and 253J bladder cancer cells.

Immunofluorescence^[1]

Cell Line:

T24 and 253J bladder cancer cells
Concentration:

0.39, 0.78, 1.56 μM (T24)
0.09, 0.19, 0.39 μM (253J)
Incubation Time:

24 h
Result:

Reduced nuclear survivin in T24 and 253J bladder cancer cells, reaching approximately 50% of control at 1.56 μM in T24 and showing greater sensitivity in 253J at 0.09-0.39 μM.

Western Blot Analysis^[1]

Cell Line:

T24 bladder cancer cells
Concentration:

1.56, 3.13 μM
Incubation Time:

24 h
Result:

Reduced total survivin protein in T24 bladder cancer cells at 1.56 and 3.13 μM after 24 h.

In Vivo

Anti-cancerApoptosis

Anti-cancer

Apoptosis

MV14 (1 mg/mL; 100 μL; intravesical administration; once weekly; for four consecutive weeks (weeks 17-21)) attenuates BBN (HY-W755252)-induced histopathological changes in bladder tumors and reduces survivin and PCNA levels while increasing active caspase-3 in C57BL/6 tumor-bearing mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (female, 6-8 weeks old, received 0.05% BBN (HY-W755252) in drinking water ad libitum for 16 weeks)^[1]
Dosage:

1 mg/mL; 100 μL per intravesical instillation
Administration:

intravesical; once weekly; four consecutive weeks (weeks 17-21)
Result:

Attenuated tumor-associated histopathological alterations in BBN-induced bladder tumors, with less urothelial disruption and less pronounced stromal invasion than vehicle-treated tumor-bearing mice.
Tumors showed urothelial cell hyperplasia with lower-grade undifferentiation and dysplasia toward the lamina propria, moderate anisocytosis and anisokaryosis, nuclear atypia, fewer binucleated cells, and fewer mitotic figures than vehicle-treated tumors.
Reduced survivin levels and decreased PCNA-positive cells in tumor tissue, while increasing active caspase-3-positive cells.

Related Protocols :

Chemical Information

CAS. Nr. 2377778-85-1
Molecular Weight 385.39
Formel C₁₅H₁₉N₃O₇S
SMILES

[O-][N+]1=C(S(=O)(C2=CC=CC=C2)=O)C(OCCNC(OC(C)(C)C)=O)=NO1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. López M, et al. Exploring MV14 as a nitric oxide-releasing strategy for bladder cancer: From synthesis to in vivo evaluation. European journal of medicinal chemistry. 2026 Sep 22;320:119331.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MV14

Alle NO Synthase Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen